Nanosphere Appoints Gregory Shipp, M.D. Vice President of Medical Affairs; Industry Veteran to Manage Relations With Clinical Community and Regulatory Bodies as Company Prepares for Commercial Product Launch

NORTHBROOK, Ill.--(BUSINESS WIRE)--July 6, 2005--Nanosphere, Inc., a nanotechnology-based life sciences company, today announced Gregory Shipp, M.D., has joined the company as its first vice president of medical affairs. Dr. Shipp brings extensive experience in medical, clinical and regulatory affairs management and a proven ability to forge strong working relationships with the medical and clinical laboratory communities. His appointment comes as Nanosphere is preparing to introduce the first commercially available system to enable the ultra-sensitive detection of DNA, RNA and proteins on a single platform.

Nanosphere's Verigene(R) System will provide the ability to simultaneously conduct ultrasensitive genomic and proteomic analysis using a single instrument. By delivering technologies that enable direct genomic detection--without complicated and time-consuming sample preparation--and protein detection that is five to six orders of magnitude more sensitive than the current standard, the Verigene System may enable faster diagnosis of diseases and the creation of more targeted therapeutics.

“Greg Shipp will bring tremendous value to Nanosphere as customers and partners assess our product's numerous applications in drug discovery, clinical diagnostics and biosecurity systems”

"Greg Shipp will bring tremendous value to Nanosphere as customers and partners assess our product's numerous applications in drug discovery, clinical diagnostics and biosecurity systems," said William Moffitt, president and chief executive officer of Nanosphere. "His knowledge of technology requirements unique to medical and clinical settings, as well as regulatory affairs, makes Greg a key addition to our management team as we bring our integrated platform to market."

Most recently, Dr. Shipp was medical director and chief medical officer for i-STAT Corporation, an Abbott Point-of-Care division, where he managed relations with laboratory medical directors and clinical physicians domestically and abroad. He also created awareness of point-of-care testing benefits through the development of post-market clinical studies.

Prior to i-STAT, Dr. Shipp served as clinical affairs director for Boston Scientific Medi-tech, where he managed the clinical evaluation of an implantable abdominal aortic stent-graft across 26 sites. Before joining Boston Scientific, he was senior medical officer for Bio-Reg Associates. There, he led clinical studies of medical devices in the areas of ophthalmology, plastic surgery, urology and bone physiology.

Dr. Shipp earned his medical degree from the University of North Carolina School of Medicine and received B.S. and M.S. degrees in biomedical engineering from Northwestern University.

About Nanosphere, Inc.

Nanosphere is a life sciences company applying proprietary nanotechnology to create new standards in medical care and public safety. With a universal Verigene product platform for the detection of nucleic acids and proteins at extraordinarily low concentrations, Nanosphere is rapidly advancing the development of assays for genomic and proteomic research, clinical laboratories and point-of-care markets. The privately held company is based in Northbrook, Illinois. Additional information is available at


Nanosphere, Inc.
Ken Bahk, Ph.D., 847-400-9000
Schwartz Communications, Inc.
Jennifer Viera, 781-684-0770

Better Be Business Wired.

Business Wire is the leading source for press releases, photos, multimedia and regulatory filings from companies and groups throughout the world.